What to Expect with GW Pharmaceuticals (GWPH) During 2016

GW Pharmaceuticals plc (GWPH) is a pharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform. GWPH commercialized the world's first plant-derived cannabinoid prescription drug, Sativex, which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States.

GWPH has an extensive product pipeline which should enable to the company to be a major player for years to come. GWPH recently reported data pertaining to its Epidiolex product and we expect 2016 to be a milestone year for the company. 

Favorable Data Presented at the American Epilepsy Society’s Annual Meeting

On Monday, the largest CBD study presented efficacy and safety data on GWPH’s Epidiolex product. The study involved 261 people (average age was 11) who suffer from severe epilepsy and have not responded adequately to other treatments.

After three months of treatment, the frequency of all seizures...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.